Services
The current COVID-19 pandemic and the race towards development of new vaccines and therapies reinforce the importance of partnering with experts on the development and validation of assays for clinical trials.
CellCarta has decades of infectious diseases experience working with many pharmaceutical and biotech partners for the development of new vaccines and therapies.
Leveraging our multiple cell-based and cell-free platforms to study immune responses and monitor protein biomarkers, our expert scientists can develop and validate assays within a turn-around time aligned with your clinical needs, enabling you to move your programs forward with confidence.
MEASURE LOW FREQUENCY ANTIGEN RESPONSES
Our scientists have extensive experience in customizing ELISpot assays to monitor the immune response to your antigens of interest and deploying those in clinical trials. An IFNγ ELISpot assay is readily available for exploratory endpoints and can be validated for secondary and primary endpoints.
We also develop and deploy FluoroSpot assays, allowing the simultaneous investigation of multiple analytes in one well. Our team validated a FluoroSpot assay to simultaneously investigate T-cell secretion of IFNγ and IL-4 in clinical samples.
UNDERSTAND IMMUNE RESPONSES BY MONITORING CYTOKINE PRODUCTION AT THE SINGLE-CELL LEVEL
We routinely develop and deploys intra-cellular cytokine staining (ICS) assays to characterize antigen-specific responses in clinical samples. Leveraging our long-standing experience in multiparametric flow cytometry, we simultaneously measure intra and cell-surface markers in individual cells and provide a complete profiling of immune cell subsets.
Our solid experience in customizing ICS assays, including careful selection of the best in vitro cellular parameters, will guarantee optimal results.
DETECT CLINICALLY RELEVANT BIOMARKERS
At CellCarta, we have a long history of working on large infectious diseases programs. With our mass spectrometry (MS) platform, we identify and measure host proteins to better characterize the immune response.
Identify and quantify correlates of protection using our two mass spectrometry approaches: unbiased liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS) and multiple reaction monitoring (MRM).
Our expertise in mass spectrometry was showcased in the following publication
See also
A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus Immunogenicity and Safety of a Quadrivalent Plant-derived Virus Like Particle Influenza Vaccine Candidate – Two Randomized Phase II Clinical Trials in 18 to 49 and ≥50 Years Old Adults